Nifty
Sensex
:
:
24358.45
80013.87
-55.05 (-0.23%)
-135.01 (-0.17%)

Pharmaceuticals & Drugs - Global

Rating :
71/99

BSE: 524742 | NSE: CAPLIPOINT

1456.20
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1430.00
  •  1465.95
  •  1422.10
  •  1431.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  127153
  •  1839.51
  •  1619.05
  •  840.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,559.10
  • 25.29
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,006.64
  • 0.16%
  • 4.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.56%
  • 1.16%
  • 17.50%
  • FII
  • DII
  • Others
  • 3.37%
  • 1.40%
  • 6.01%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 17.72
  • 11.39

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.70
  • 6.32

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 16.34
  • 15.81

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.87
  • 18.02
  • 20.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.24
  • 3.93
  • 4.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.63
  • 12.28
  • 13.63

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
453.22
389.28
16.43%
435.50
372.07
17.05%
410.06
359.05
14.21%
395.32
346.33
14.15%
Expenses
307.99
265.35
16.07%
293.22
262.70
11.62%
272.66
253.47
7.57%
268.79
244.15
10.09%
EBITDA
145.23
123.93
17.19%
142.28
109.37
30.09%
137.40
105.58
30.14%
126.53
102.18
23.83%
EBIDTM
32.04%
31.84%
32.67%
29.39%
33.51%
29.41%
32.01%
29.50%
Other Income
17.29
11.40
51.67%
17.18
14.15
21.41%
20.43
16.48
23.97%
12.04
13.94
-13.63%
Interest
0.15
0.23
-34.78%
0.17
0.36
-52.78%
0.18
0.14
28.57%
0.28
0.06
366.67%
Depreciation
16.40
11.13
47.35%
13.90
11.43
21.61%
11.76
11.46
2.62%
11.38
10.97
3.74%
PBT
145.97
123.97
17.75%
145.39
111.73
30.13%
145.89
110.46
32.07%
126.91
105.09
20.76%
Tax
24.80
22.81
8.72%
25.59
14.35
78.33%
29.86
18.42
62.11%
22.76
18.78
21.19%
PAT
121.17
101.16
19.78%
119.80
97.38
23.02%
116.03
92.04
26.06%
104.15
86.31
20.67%
PATM
26.74%
25.99%
27.51%
26.17%
28.30%
25.63%
26.35%
24.92%
EPS
16.01
13.45
19.03%
15.43
12.84
20.17%
15.12
12.09
25.06%
13.62
11.21
21.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Net Sales
1,694.10
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
251.77
173.09
Net Sales Growth
15.50%
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
 
Cost Of Goods Sold
724.18
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
Gross Profit
969.92
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
116.15
70.50
GP Margin
57.25%
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
Total Expenditure
1,142.66
1,026.21
874.88
737.04
603.13
416.84
344.52
276.84
174.51
192.06
136.90
Power & Fuel Cost
-
25.53
21.40
16.36
14.81
13.76
10.98
9.91
7.56
8.61
3.07
% Of Sales
-
1.74%
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
Employee Cost
-
136.12
114.74
101.97
67.15
45.58
37.61
29.71
17.92
18.24
12.63
% Of Sales
-
9.28%
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
Manufacturing Exp.
-
90.99
82.01
69.85
68.23
43.49
37.11
28.56
14.33
16.04
7.42
% Of Sales
-
6.20%
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
General & Admin Exp.
-
85.38
66.68
38.53
25.50
20.82
12.27
13.78
8.15
7.97
6.54
% Of Sales
-
5.82%
5.25%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
Selling & Distn. Exp.
-
18.78
27.52
18.03
9.95
2.08
5.92
9.41
2.29
2.85
1.46
% Of Sales
-
1.28%
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
Miscellaneous Exp.
-
6.20
5.02
20.56
4.33
2.33
2.45
0.55
3.10
2.72
1.46
% Of Sales
-
0.42%
0.40%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
EBITDA
551.44
440.52
394.53
324.25
260.07
231.85
195.32
124.81
64.21
59.71
36.19
EBITDA Margin
32.55%
30.03%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
Other Income
66.94
56.52
38.89
27.93
41.33
19.03
12.67
9.96
3.66
3.03
3.72
Interest
0.78
0.78
0.70
1.59
0.32
0.58
0.61
0.52
0.34
0.97
0.68
Depreciation
53.44
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
PBT
564.16
451.27
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Tax
103.01
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
12.26
9.76
Tax Rate
18.26%
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
PAT
461.15
376.26
299.84
242.27
215.00
176.56
144.78
95.61
45.77
41.04
25.85
PAT before Minority Interest
456.82
376.99
308.45
251.43
215.08
176.56
144.63
95.50
45.77
41.13
25.93
Minority Interest
-4.33
-0.73
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
PAT Margin
27.22%
25.65%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
PAT Growth
22.36%
25.49%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
 
EPS
60.68
49.51
39.45
31.88
28.29
23.23
19.05
12.58
6.02
5.40
3.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Shareholder's Funds
1,880.48
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
93.19
61.74
Share Capital
89.76
89.74
89.71
89.71
51.05
15.12
15.12
15.11
15.11
15.11
Total Reserves
1,775.35
1,378.74
1,081.33
848.76
575.01
345.42
209.56
111.40
78.08
46.63
Non-Current Liabilities
2.30
12.55
17.39
24.86
23.42
27.86
19.90
13.69
10.39
10.42
Secured Loans
0.00
0.00
0.00
0.02
0.29
0.32
0.48
0.73
0.88
2.07
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
7.78
8.48
5.69
5.23
0.13
0.00
0.40
1.63
0.82
0.81
Current Liabilities
268.00
207.68
142.85
144.32
86.11
108.67
113.36
125.04
124.97
107.58
Trade Payables
164.37
155.94
88.50
64.14
60.47
94.23
78.60
55.71
41.56
31.50
Other Current Liabilities
99.94
48.68
51.87
79.28
24.20
13.86
33.09
60.39
72.11
66.42
Short Term Borrowings
3.41
0.50
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.05
Short Term Provisions
0.28
2.56
2.48
0.91
1.44
0.58
1.67
8.94
11.25
9.60
Total Liabilities
2,177.57
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
Net Block
279.81
286.57
305.34
272.50
226.84
169.48
151.83
144.23
113.13
102.24
Gross Block
480.32
445.74
422.58
354.79
271.51
231.79
195.15
180.76
142.71
123.06
Accumulated Depreciation
200.51
159.17
117.24
82.29
44.67
62.31
43.31
36.53
29.58
20.82
Non Current Assets
623.11
432.29
349.04
303.23
248.83
196.34
179.16
148.61
146.95
131.30
Capital Work in Progress
220.71
17.73
13.88
20.12
9.70
15.29
3.42
0.23
30.63
24.54
Non Current Investment
70.52
37.01
0.66
0.56
0.33
0.33
13.24
0.44
0.45
0.44
Long Term Loans & Adv.
51.68
89.90
7.92
10.05
11.95
11.23
10.67
3.71
2.75
3.67
Other Non Current Assets
0.39
1.08
21.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,554.46
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
81.87
48.61
Current Investments
159.17
51.97
10.54
60.23
69.62
46.34
4.20
0.00
0.00
0.00
Inventories
288.22
227.31
179.01
238.23
37.45
28.46
22.29
18.81
13.66
9.79
Sundry Debtors
394.06
317.05
279.36
228.96
159.81
125.88
33.02
7.95
5.66
0.09
Cash & Bank
493.48
462.99
438.33
223.43
152.99
79.28
93.07
68.10
45.37
26.82
Other Current Assets
219.53
13.61
20.25
14.87
73.83
24.16
26.63
23.67
17.18
11.90
Short Term Loans & Adv.
196.81
224.89
87.08
56.81
64.61
17.28
19.31
12.58
11.08
8.16
Net Current Assets
1,286.46
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
Total Assets
2,177.57
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Cash From Operating Activity
271.37
336.73
268.61
44.68
83.42
66.49
67.61
42.40
49.88
59.83
PBT
451.35
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Adjustment
11.77
30.44
23.09
7.09
19.12
14.84
8.61
3.87
6.21
2.14
Changes in Working Capital
-103.75
1.96
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
Cash after chg. in Working capital
359.37
418.22
334.75
99.44
125.94
102.84
91.16
58.78
61.56
67.15
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-88.00
-81.49
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-217.58
-376.77
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
Net Fixed Assets
-56.57
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
Net Investments
-169.44
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
Others
8.43
-257.59
-40.57
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
Cash from Financing Activity
-28.17
-40.68
-23.98
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
Net Cash Inflow / Outflow
25.62
-80.72
215.19
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
Opening Cash & Equivalents
150.76
231.57
220.77
150.65
77.17
91.31
66.55
45.37
26.82
16.84
Closing Cash & Equivalent
177.56
150.76
435.72
220.77
150.65
77.17
91.31
68.10
45.37
26.82

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Book Value (Rs.)
235.91
183.89
144.94
114.21
78.03
47.69
29.73
16.25
11.84
7.68
ROA
19.29%
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
ROE
23.68%
24.77%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
ROCE
26.85%
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
Fixed Asset Turnover
3.17
2.92
2.73
2.76
2.58
2.53
2.14
1.48
1.89
2.00
Receivable days
88.48
85.74
87.41
82.19
80.37
53.72
18.62
10.40
4.17
1.00
Inventory Days
64.15
58.42
71.75
58.28
18.54
17.16
18.68
24.83
17.00
21.31
Payable days
88.14
80.02
59.05
28.33
65.76
89.68
88.17
103.48
69.75
79.69
Cash Conversion Cycle
64.48
64.14
100.11
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
Total Debt/Equity
0.00
0.00
0.01
0.04
0.00
0.00
0.00
0.02
0.02
0.06
Interest Cover
579.65
552.17
198.25
843.86
391.22
309.72
235.08
179.35
56.11
53.29

News Update:


  • Caplin Point Laboratories’ arm gets USFDA’s approval for Ephedrine Sulfate Injection
    19th Jul 2024, 11:28 AM

    Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia

    Read More
  • Caplin Point’s arm gets USFDA’s approval for Phenylephrine Hydrochloride Ophthalmic Solution
    24th May 2024, 11:27 AM

    Phenylephrine hydrochloride Ophthalmic Solution USP 2.5% and 10% is indicated to dilate the pupil of the eyes

    Read More
  • Caplin Point Lab - Quarterly Results
    16th May 2024, 13:55 PM

    Read More
  • Caplin Point gets Colombia's INVIMA approval for Softgel Capsules division
    6th May 2024, 11:40 AM

    The site inspection of Unit-1 was completed on May 3

    Read More
  • Caplin Point Laboratories’ arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution
    16th Apr 2024, 12:30 PM

    Ofloxacin Ophthalmic Solution USP 0.3% had US sales of around $52 million for the 12- month period ending December 2023

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.